Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Compare

662 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTGX Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Protagonist

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTGX Stock 12 Month Forecast

Average Price Target

$70.20

▲(30.43%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $70.20 with a high forecast of $82.00 and a low forecast of $61.00. The average price target represents a 30.43% change from the last price of $53.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","41":"$41","55":"$55","69":"$69","83":"$83"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,41,55,69,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.15,52.6,55.05,57.5,59.95,62.4,64.85,67.3,69.75,72.2,74.65,77.1,79.55,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.15,51.69230769230769,53.23461538461538,54.776923076923076,56.31923076923077,57.86153846153846,59.40384615384615,60.94615384615385,62.488461538461536,64.03076923076924,65.57307692307693,67.11538461538461,68.65769230769232,{"y":70.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.15,50.98461538461538,51.81923076923077,52.65384615384615,53.488461538461536,54.323076923076925,55.15769230769231,55.99230769230769,56.82692307692308,57.66153846153846,58.496153846153845,59.330769230769235,60.16538461538462,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$82.00

Average Price Target$70.20

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$54

Hold

0.33%

Upside

Reiterated

06/05/25

Protagonist Therapeutics' overall score is driven by a mix of financial performance and technical analysis. The positive trend in stock price is offset by financial instability, high valuation metrics, and the absence of consistent revenue growth.

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$80

Buy

48.64%

Upside

Reiterated

06/03/25

Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera

Kaveri PohlmanClear Street

Clear Street

$65→$62

Buy

15.20%

Upside

Reiterated

06/03/25

Protagonist Therapeutics (PTGX) Receives a Buy from Clear Street

Julian HarrisonBTIG

BTIG

$82

Buy

52.36%

Upside

Reiterated

06/02/25

Protagonist Therapeutics' Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation

Brian ChengJ.P. Morgan

J.P. Morgan

$66

Buy

22.63%

Upside

Reiterated

06/02/25

J.P. Morgan Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

Tara BancroftTD Cowen

TD Cowen

$65

Buy

20.77%

Upside

Initiated

06/01/25

Protagonist Therapeutics (PTGX) Gets a Buy from TD Cowen

Yun ZhongWedbush

Wedbush

$70

Buy

30.06%

Upside

Reiterated

05/07/25

Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships

Roger SongJefferies

Jefferies

$68

Buy

26.35%

Upside

Reiterated

04/10/25

Promising Potential of Protagonist Therapeutics' Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song

Evan SeigermanBMO Capital

BMO Capital

$62→$72

Buy

33.78%

Upside

Reiterated

03/11/25

Protagonist Therapeutics price target raised to $72 from $62 at BMO CapitalProtagonist Therapeutics price target raised to $72 from $62 at BMO Capital

Srikripa DevarakondaTruist Financial

Truist Financial

$60→$76

Buy

41.21%

Upside

Reiterated

03/11/25

Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial

Jonathan WollebenCitizens JMP

Citizens JMP

$61

Buy

13.34%

Upside

Reiterated

03/10/25

Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of IcotrokinraWe think icotrokinra is likely to be approved (90% POS) and we model peak sales of >$5B, which is in line with JNJ’s projections (our coverage here).

Richard Law CFAGoldman Sachs

Goldman Sachs

$43→$38

Hold

-29.39%

Downside

Reiterated

02/24/25

Protagonist Therapeutics (PTGX) PT Lowered to $38 at Goldman SachsGoldman Sachs lowered its price target on Protagonist Therapeutics (NASDAQ: PTGX) to $38.00 (from $43.00) while maintaining a Neutral rating.

Tim ChiangCapital One Financial

Capital One Financial

$48

Buy

-10.81%

Downside

Assigned

08/06/24

Protagonist Therapeutics Receives 'Buy' Rating on Strong Performance and Promising Pipeline

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$54

Hold

0.33%

Upside

Reiterated

06/05/25

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$80

Buy

48.64%

Upside

Reiterated

06/03/25

Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera

Kaveri PohlmanClear Street

Clear Street

$65→$62

Buy

15.20%

Upside

Reiterated

06/03/25

Protagonist Therapeutics (PTGX) Receives a Buy from Clear Street

Julian HarrisonBTIG

BTIG

$82

Buy

52.36%

Upside

Reiterated

06/02/25

Protagonist Therapeutics' Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation

Brian ChengJ.P. Morgan

J.P. Morgan

$66

Buy

22.63%

Upside

Reiterated

06/02/25

J.P. Morgan Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

Tara BancroftTD Cowen

TD Cowen

$65

Buy

20.77%

Upside

Initiated

06/01/25

Protagonist Therapeutics (PTGX) Gets a Buy from TD Cowen

Yun ZhongWedbush

Wedbush

$70

Buy

30.06%

Upside

Reiterated

05/07/25

Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships

Roger SongJefferies

Jefferies

$68

Buy

26.35%

Upside

Reiterated

04/10/25

Promising Potential of Protagonist Therapeutics' Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song

Evan SeigermanBMO Capital

BMO Capital

$62→$72

Buy

33.78%

Upside

Reiterated

03/11/25

Protagonist Therapeutics price target raised to $72 from $62 at BMO CapitalProtagonist Therapeutics price target raised to $72 from $62 at BMO Capital

Srikripa DevarakondaTruist Financial

Truist Financial

$60→$76

Buy

41.21%

Upside

Reiterated

03/11/25

Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial

Jonathan WollebenCitizens JMP

Citizens JMP

$61

Buy

13.34%

Upside

Reiterated

03/10/25

Richard Law CFAGoldman Sachs

Goldman Sachs

$43→$38

Hold

-29.39%

Downside

Reiterated

02/24/25

Tim ChiangCapital One Financial

Capital One Financial

$48

Buy

-10.81%

Downside

Assigned

08/06/24

Protagonist Therapeutics Receives 'Buy' Rating on Strong Performance and Promising Pipeline

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

1 Month

xxx

Success Rate

10/13 ratings generated profit

Average Return

+11.68%

assigned a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +11.68% per trade.

3 Months

xxx

Success Rate

9/11 ratings generated profit

Average Return

+16.59%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +16.59% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

21/21 ratings generated profit

Average Return

+76.27%

reiterated a buy rating 3 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +76.27% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+150.49%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +150.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTGX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTGX has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PTGX average Analyst price target in the past 3 months is 70.20.

Each month's total comprises the sum of three months' worth of ratings.

PTGX Financial Forecast

PTGX Earnings Forecast

Next quarter’s earnings estimate for PTGX is -$0.59 with a range of -$0.76 to -$0.24. The previous quarter’s EPS was -$0.18. PTGX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year PTGX has Outperformed its overall industry.

PTGX Sales Forecast

Next quarter’s sales forecast for PTGX is $6.61M with a range of $0.00 to $28.30M. The previous quarter’s sales results were $28.32M. PTGX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year PTGX has Outperformed its overall industry.

PTGX Stock Forecast FAQ

What is PTGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Protagonist Therapeutics Inc’s 12-month average price target is 70.20.

What is PTGX’s upside potential, based on the analysts’ average price target?

Protagonist Therapeutics Inc has 30.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTGX a Buy, Sell or Hold?

Protagonist Therapeutics Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Protagonist Therapeutics Inc’s price target?

The average price target for Protagonist Therapeutics Inc is 70.20. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $82.00 ,the lowest forecast is $61.00. The average price target represents 30.43% Increase from the current price of $53.82.

What do analysts say about Protagonist Therapeutics Inc?

Protagonist Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of PTGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

PTGX Analyst Ratings

PTGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protagonist Therapeutics

PTGX Analyst Recommendation Trends

PTGX Financial Forecast

PTGX Earnings Forecast

PTGX Sales Forecast

PTGX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts